Ardelyx (ARDX) Competitors $4.53 -0.13 (-2.79%) (As of 09:40 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends ARDX vs. CRNX, KRYS, ACLX, ADMA, RARE, BHVN, APLS, IMVT, SRRK, and RNAShould you be buying Ardelyx stock or one of its competitors? The main competitors of Ardelyx include Crinetics Pharmaceuticals (CRNX), Krystal Biotech (KRYS), Arcellx (ACLX), ADMA Biologics (ADMA), Ultragenyx Pharmaceutical (RARE), Biohaven (BHVN), Apellis Pharmaceuticals (APLS), Immunovant (IMVT), Scholar Rock (SRRK), and Avidity Biosciences (RNA). These companies are all part of the "pharmaceutical products" industry. Ardelyx vs. Crinetics Pharmaceuticals Krystal Biotech Arcellx ADMA Biologics Ultragenyx Pharmaceutical Biohaven Apellis Pharmaceuticals Immunovant Scholar Rock Avidity Biosciences Ardelyx (NASDAQ:ARDX) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, community ranking, valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and media sentiment. Which has more volatility & risk, ARDX or CRNX? Ardelyx has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500. Comparatively, Crinetics Pharmaceuticals has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500. Does the MarketBeat Community favor ARDX or CRNX? Ardelyx received 375 more outperform votes than Crinetics Pharmaceuticals when rated by MarketBeat users. However, 69.20% of users gave Crinetics Pharmaceuticals an outperform vote while only 67.52% of users gave Ardelyx an outperform vote. CompanyUnderperformOutperformArdelyxOutperform Votes53067.52% Underperform Votes25532.48% Crinetics PharmaceuticalsOutperform Votes15569.20% Underperform Votes6930.80% Is ARDX or CRNX more profitable? Crinetics Pharmaceuticals has a net margin of 0.00% compared to Ardelyx's net margin of -28.82%. Crinetics Pharmaceuticals' return on equity of -36.12% beat Ardelyx's return on equity.Company Net Margins Return on Equity Return on Assets Ardelyx-28.82% -46.60% -21.49% Crinetics Pharmaceuticals N/A -36.12%-31.89% Which has stronger valuation & earnings, ARDX or CRNX? Ardelyx has higher revenue and earnings than Crinetics Pharmaceuticals. Ardelyx is trading at a lower price-to-earnings ratio than Crinetics Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArdelyx$251.85M4.26-$66.07M-$0.30-15.10Crinetics Pharmaceuticals$1.04M4,896.64-$214.53M-$3.73-14.71 Does the media refer more to ARDX or CRNX? In the previous week, Crinetics Pharmaceuticals had 6 more articles in the media than Ardelyx. MarketBeat recorded 12 mentions for Crinetics Pharmaceuticals and 6 mentions for Ardelyx. Crinetics Pharmaceuticals' average media sentiment score of 1.12 beat Ardelyx's score of 0.33 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ardelyx 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Crinetics Pharmaceuticals 6 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals hold more shares of ARDX or CRNX? 58.9% of Ardelyx shares are held by institutional investors. Comparatively, 98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. 5.9% of Ardelyx shares are held by insiders. Comparatively, 6.0% of Crinetics Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Do analysts prefer ARDX or CRNX? Ardelyx currently has a consensus price target of $10.42, suggesting a potential upside of 129.95%. Crinetics Pharmaceuticals has a consensus price target of $70.82, suggesting a potential upside of 29.09%. Given Ardelyx's higher possible upside, analysts clearly believe Ardelyx is more favorable than Crinetics Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ardelyx 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.88Crinetics Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.91 SummaryCrinetics Pharmaceuticals beats Ardelyx on 11 of the 19 factors compared between the two stocks. Ad Diversified Trading InstituteGenesis leading the smart algo revolution?I’m revealing an exciting breakthrough that can help trade the markets unlike anything you’ve ever seen before… Because with my BRAND NEW smart algo you’ll always have a constant stream of alerts firing off in your back pocket to choose from. Here’s why: It does all the heavy lifting for you… automatically. Stock Ticker, Entry Price, Profit Target, Stop Loss, and even an Individual Chart!You’ll want to see what I’ve put on this page right here Get Ardelyx News Delivered to You Automatically Sign up to receive the latest news and ratings for ARDX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARDX vs. The Competition Export to ExcelMetricArdelyxPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.07B$6.85B$5.14B$9.31BDividend YieldN/A3.06%4.81%4.06%P/E Ratio-15.1010.71135.1917.53Price / Sales4.26287.971,224.59140.21Price / CashN/A56.6540.6537.95Price / Book6.295.394.884.92Net Income-$66.07M$152.04M$118.97M$225.78M7 Day Performance-14.85%-4.32%15.53%-1.58%1 Month Performance-8.67%2.80%15.54%6.67%1 Year Performance-27.87%17.30%34.63%22.48% Ardelyx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARDXArdelyx3.8431 of 5 stars$4.53-2.8%$10.42+129.9%-21.2%$1.07B$251.85M-15.10267CRNXCrinetics Pharmaceuticals4.2151 of 5 stars$54.15+0.9%$70.82+30.8%+60.7%$5.02B$1.04M-14.39210Analyst ForecastShort Interest ↓Positive NewsKRYSKrystal Biotech4.3121 of 5 stars$172.13+5.2%$206.67+20.1%+46.0%$4.95B$50.70M92.45229Analyst ForecastACLXArcellx3.0444 of 5 stars$85.00+1.4%$105.93+24.6%+60.5%$4.60B$155.82M-118.03130ADMAADMA Biologics3.8605 of 5 stars$19.00+2.2%$21.25+11.8%+343.6%$4.49B$382.81M68.32530Short Interest ↓RAREUltragenyx Pharmaceutical4.5688 of 5 stars$46.11+0.7%$87.46+89.7%-2.2%$4.26B$434.25M-7.081,276BHVNBiohaven3.8327 of 5 stars$40.94+6.4%$63.00+53.9%+0.3%$4.14B$462.51M-4.11239Analyst ForecastAPLSApellis Pharmaceuticals4.721 of 5 stars$33.24+0.2%$49.94+50.3%-34.5%$4.13B$396.59M-16.35702Analyst DowngradeShort Interest ↓Positive NewsIMVTImmunovant1.4499 of 5 stars$27.45+4.5%$47.89+74.5%-34.7%$4.03BN/A-11.84120SRRKScholar Rock3.9591 of 5 stars$43.01+2.5%$40.43-6.0%+130.0%$4.03B$33.19M-18.35140Positive NewsRNAAvidity Biosciences2.5121 of 5 stars$33.62+3.5%$63.60+89.2%+278.5%$4.01B$10.12M-11.28190Gap Down Related Companies and Tools Related Companies CRNX Competitors KRYS Competitors ACLX Competitors ADMA Competitors RARE Competitors BHVN Competitors APLS Competitors IMVT Competitors SRRK Competitors RNA Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ARDX) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | Sponsored2025’s #1 Trump TradeAll the Energy You Need to Power Your Entire Life... Could Fit Inside This Single Soda Can. Three Companies...The Oxford Club | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored50-year Wall Street legend: “Sell this tech stock NOW”Something very strange is happening to U.S. stocks following President Trump's victory... And this could s...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ardelyx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ardelyx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
